DK1994410T3 - Fremgangsmåder og kits til tidlig påvisning af cancer eller disposition derfor - Google Patents

Fremgangsmåder og kits til tidlig påvisning af cancer eller disposition derfor

Info

Publication number
DK1994410T3
DK1994410T3 DK07706065.5T DK07706065T DK1994410T3 DK 1994410 T3 DK1994410 T3 DK 1994410T3 DK 07706065 T DK07706065 T DK 07706065T DK 1994410 T3 DK1994410 T3 DK 1994410T3
Authority
DK
Denmark
Prior art keywords
kits
methods
cancer
determining
disposition
Prior art date
Application number
DK07706065.5T
Other languages
English (en)
Inventor
Nadir Arber
Original Assignee
Medical Res Fund Of Tel Aviv Sourasky Medical Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Res Fund Of Tel Aviv Sourasky Medical Ct filed Critical Medical Res Fund Of Tel Aviv Sourasky Medical Ct
Application granted granted Critical
Publication of DK1994410T3 publication Critical patent/DK1994410T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK07706065.5T 2006-01-31 2007-01-31 Fremgangsmåder og kits til tidlig påvisning af cancer eller disposition derfor DK1994410T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76337806P 2006-01-31 2006-01-31
PCT/IL2007/000122 WO2007088537A2 (en) 2006-01-31 2007-01-31 Methods and kits for early detection of cancer or predisposition thereto

Publications (1)

Publication Number Publication Date
DK1994410T3 true DK1994410T3 (da) 2011-01-31

Family

ID=38001788

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07706065.5T DK1994410T3 (da) 2006-01-31 2007-01-31 Fremgangsmåder og kits til tidlig påvisning af cancer eller disposition derfor

Country Status (12)

Country Link
US (1) US9394569B2 (da)
EP (1) EP1994410B1 (da)
JP (1) JP5091163B2 (da)
AT (1) ATE486285T1 (da)
DE (1) DE602007010108D1 (da)
DK (1) DK1994410T3 (da)
ES (1) ES2355388T3 (da)
IL (1) IL193097A (da)
PL (1) PL1994410T3 (da)
PT (1) PT1994410E (da)
SI (1) SI1994410T1 (da)
WO (1) WO2007088537A2 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486285T1 (de) 2006-01-31 2010-11-15 Medical Res Fund Of Tel Aviv S Verfahren zur früherkennung von krebs
WO2009074988A1 (en) * 2007-12-10 2009-06-18 Medical Research Fund Of Tel Aviv Sourasky Medical Center Methods of diagnosing cancer
EP2358912B1 (en) * 2008-10-30 2016-10-12 Caris Life Sciences Switzerland Holdings GmbH Methods for assessing rna patterns
WO2011109440A1 (en) 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings Biomarkers for theranostics
GB2463401B (en) * 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
US20140148348A1 (en) 2010-01-13 2014-05-29 Christine Kuslich Dectection of gastrointestinal disorders
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
AU2011256064B2 (en) 2010-05-21 2016-09-15 The Governors Of The University Of Alberta Methods for the assessment of colorectal cancer and colorectal polyps by measurement of metabolites in urine
EP3052651B1 (en) 2013-10-01 2019-11-27 Life Technologies Corporation Systems and methods for detecting structural variants
ES2939298T3 (es) 2017-05-21 2023-04-20 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Combinación de marcadores para el diagnóstico del cáncer
EP3447154A1 (en) * 2017-08-23 2019-02-27 Instytut Genetyki Sadowej Jolanta Powierska - Czarny Method for detection of mutations, polymorphisms and specific dna sequences on dna matrices with dna imaging techniques for the use in medical diagnostics and forensic genetics
US20200408761A1 (en) 2018-02-28 2020-12-31 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing and treating bladder cancer
JP7462632B2 (ja) 2018-11-30 2024-04-05 カリス エムピーアイ インコーポレイテッド 次世代分子プロファイリング
CN110777213A (zh) * 2019-11-05 2020-02-11 武汉科技大学 一种潜伏期胃癌诊断试剂盒
WO2021112918A1 (en) 2019-12-02 2021-06-10 Caris Mpi, Inc. Pan-cancer platinum response predictor
US11840720B2 (en) 2019-12-23 2023-12-12 Metabolomic Technologies Inc. Urinary metabolomic biomarkers for detecting colorectal cancer and polyps

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07500411A (ja) * 1991-02-05 1995-01-12 ファロク セィディ 癌胎児性抗原を検出するための簡易検査法
US5741650A (en) * 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US7081516B2 (en) * 2002-08-26 2006-07-25 Case Western Reserve University Methods for categorizing patients
EP1497642A2 (en) * 2002-03-19 2005-01-19 Tularik, Inc. Gene amplification in cancer
US20040097448A1 (en) * 2002-11-19 2004-05-20 Isis Pharmaceuticals Inc. Modulation of CD24 expression
WO2005024603A2 (en) * 2003-09-10 2005-03-17 The Board Of Regents Of The University Of Texas System Methods for detecting, diagnosing and treating human renal cell carcinoma
CA2549913A1 (en) * 2003-11-26 2005-06-16 The Ohio State University Research Foundation Polymorphic cd24 genotypes that are predictive of multiple sclerosis risk and progression
CA2453198A1 (en) * 2004-01-07 2005-07-07 Wei-Ping Min Quantification and generation of immune suppressive exosomes
US7666583B2 (en) * 2004-02-19 2010-02-23 Yale University Identification of cancer protein biomarkers using proteomic techniques
ATE486285T1 (de) 2006-01-31 2010-11-15 Medical Res Fund Of Tel Aviv S Verfahren zur früherkennung von krebs

Also Published As

Publication number Publication date
IL193097A0 (en) 2009-02-11
EP1994410B1 (en) 2010-10-27
JP5091163B2 (ja) 2012-12-05
US9394569B2 (en) 2016-07-19
SI1994410T1 (sl) 2011-03-31
PL1994410T3 (pl) 2011-12-30
ES2355388T3 (es) 2011-03-25
WO2007088537A2 (en) 2007-08-09
JP2009525041A (ja) 2009-07-09
IL193097A (en) 2013-03-24
DE602007010108D1 (da) 2010-12-09
US20100062450A1 (en) 2010-03-11
ATE486285T1 (de) 2010-11-15
WO2007088537A3 (en) 2007-10-25
EP1994410A2 (en) 2008-11-26
PT1994410E (pt) 2011-01-10

Similar Documents

Publication Publication Date Title
DK1994410T3 (da) Fremgangsmåder og kits til tidlig påvisning af cancer eller disposition derfor
EA201390149A1 (ru) Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток
BRPI0607508A2 (pt) métodos e ácidos nucléicos para análise de distúrbios proliferativos celulares
RU2013146242A (ru) Fgfr и его лиганды в качестве биомаркеров рака молочной железы у hr-положительных индивидуумов
WO2010033371A3 (en) Molecular markers for lung and colorectal carcinomas
WO2009047756A3 (en) Methods and kits for diagnosing lung cancer
EP1810026A4 (en) B7-H1 AND METHOD FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER
WO2008140463A3 (en) Biomarker panels for assessing radiation injury and exposure
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2010005991A3 (en) Circulating tumor and tumor stem cell detection using genomic specific probes
WO2010019550A3 (en) Method of identifying disease risk factors
WO2005084109A3 (en) Cancer specific gene mh15
WO2004030511A3 (en) Prostate cancer biomarkers
UY32698A (es) Marcadores de riesgo para enfermedades cardiovasculares
WO2011021041A3 (en) Survival prognostic assay
EP2212700B8 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
EP1987165A4 (en) Gene with influence on the human memory
ATE521385T1 (de) Automatische bestimmung eines t-schock- empfänglichen fensters
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
EP2029745A4 (en) DIAGNOSTIC PROCEDURES AND MARKERS
WO2010020619A3 (en) Susceptibility to dasatinib
WO2006034456A3 (en) Compositions and methods for detecting and treating tumors
WO2008099608A1 (ja) 炎症性腸疾患の診断方法